



**King Pharmaceuticals, Inc.**  
Research and Development  
CentreGreen Two, Suite 300  
4000 CentreGreen Way  
Cary, NC 27513

Eric G. Carter, PhD, MD  
Chief Science Officer

June 4, 2008

Dear Healthcare Professional:

We would like to inform you that after careful consideration, King Pharmaceuticals<sup>®</sup>, Inc. has decided to discontinue the manufacture of CORTISPORIN<sup>®</sup> Ophthalmic Suspension (neomycin and polymyxin B sulfates and hydrocortisone ophthalmic suspension). CORTISPORIN<sup>®</sup> Ophthalmic Suspension will remain available through pharmacies and wholesalers until current supplies are depleted. This decision is based upon many factors, including our understanding of current medical therapy and the availability of alternative therapies.

CORTISPORIN<sup>®</sup> Ophthalmic Suspension is distributed through King Pharmaceuticals<sup>®</sup>, Inc. No additional product will be available after King, pharmacy, and wholesaler supplies are exhausted. If you have any questions or concerns, you may contact our Professional Information Services Department at 800-776-3637.

CORTISPORIN<sup>®</sup> Ophthalmic Suspension (neomycin and polymyxin B sulfates and hydrocortisone ophthalmic suspension) is a sterile antimicrobial and anti-inflammatory suspension indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists.

**Important Safety Information:**

CORTISPORIN<sup>®</sup> Ophthalmic Suspension is contraindicated in most viral diseases of the cornea and conjunctiva including: epithelial herpes simplex keratitis (dendritic keratitis), vaccinia and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. Adverse reactions have occurred with corticosteroid/anti-infective combination drugs which can be attributed to the corticosteroid component, the anti-infective component, or the combination. The exact incidence is not known. Reactions occurring most often from the presence of the anti-infective ingredient are allergic sensitization reactions including itching, swelling, and conjunctival erythema (see WARNINGS). More serious hypersensitivity reactions, including anaphylaxis, have been reported rarely. The reactions due to the corticosteroid component in decreasing order of frequency are: elevation of intraocular pressure (IOP) with possible development of glaucoma, and infrequent optic nerve damage; posterior subcapsular cataract formation; and delayed wound healing.

Sincerely,

A handwritten signature in black ink that reads "Eric Carter".

Eric Carter, PhD, MD  
Chief Science Officer

**Please see accompanying full Prescribing Information.**

CORTISPORIN is a registered trademark of King Pharmaceuticals Research and Development, Inc., a wholly owned subsidiary of King Pharmaceuticals<sup>®</sup>, Inc.

Copyright © 2008 King Pharmaceuticals<sup>®</sup>, Inc. All rights reserved. MSB0004 Printed in U.S.A. 6/2008